Alliance Foundation Trials Open Largest Global Phase III Trial of Targeted Therapy for HR+/HER2- Early Breast Cancer

The Alliance Foundation Trials, LLC (AFT), the Austrian Breast & Colorectal Cancer Study Group (ABCSG), and Pfizer Inc. recently launched the Palbociclib Collaborative Adjuvant Study, or PALLAS. This global phase III clinical trial for patients with early-stage breast cancer is being conducted in conjunction with Breast International Group (BIG), German Breast Group (GBG), National Surgical Adjuvant Breast and Bowel Project (NSABP), and PrECOG, LLC (PrECOG).

Read more

Funding Support
Alliance Researchers Approved for $4.3 Million Research Funding Awards

Two Alliance researchers recently received multi-year awards from the Patient-Centered Outcomes Research Institute (PCORI) to fund comparative effectiveness research that will help patients and their providers make better informed decisions about their care, including cancer care. Ronald C. Chen, MD, MPH, of University of North Carolina at Chapel Hill, and Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, are members of the Alliance American College of Surgeons Clinical Research Program's Cancer Care Delivery Research Committee. Read more

Spotlight on Trials
Two Pivotal Alliance Trials Address Rare
Population Subsets in Thyroid Cancer

Hürthle Cell Thyroid Cancer

**Alliance A091302** - Thyroid cancers of follicular origin consist of several histologic subtypes with diverse genetic and biologic features that directly influence clinical behavior and response to systematic therapies. Papillary thyroid cancer (PTC), representing 80 percent of all thyroid cancers, follicular thyroid cancer, and Hürthle cell thyroid cancer make up a group of malignancies known as differentiated thyroid cancer (DTC). [Read more]

Advanced Anaplastic Thyroid Cancer

**Alliance A091305** - While thyroid cancer is the most common endocrine malignancy, anaplastic thyroid cancer (ATC) is extremely rare. This year, the estimated incidence rate for thyroid cancer in the United States is about 62,450 newly diagnosed cases, of which ATC comprises less than 2 percent.[1-3] [Read more]

---

**Edith A. Perez, MD**, has stepped down as Vice Chair of **Alliance for Clinical Trials in Oncology** for an exciting new opportunity. Dr. Perez is now Vice President and Head of Genentech/Roche BioOncology U.S. Medical Affairs. In her new role, she will provide strategic and scientific leadership for all BioOncology Medical Affairs activities in the U.S. [Read more]

---

**Introducing**

![Member Services Enhancement Task Force](memberenhancement@alliancenctn.org)

Earlier this year, the Alliance convened the **Member Services Enhancement Task Force** to help improve the overall facilitation and execution of Alliance work. The task force is charged with determining the needs of Alliance institutional members, enhancing Alliance member services accordingly, and improving Alliance operations. The task force seeks to assist institutional research staff in the day-to-day conduct of Alliance studies. The four major areas that the task force is focusing on include study coordination, membership and institutional network management, clinical trials reimbursement and payment mechanisms, and education, training and communications. [Read more]